Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP 2

STEP 2

Semaglutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
t2d
Official title
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2018-06 → 2020-03
Participants
1210
Duration
68 weeks
Registry
NCT03552757

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
semaglutide 2.4 mgt2d681210−10.6 % vs −3.1 %
Δ −7.5 pp
−9.6 % vs −3.4 %
Δ −6.2 pp
−1.6 vs −0.46.2 vs 3.511.6 vs 13.933.7 vs 9.221.8 vs 2.79.9 vs 9.2−3.9 vs −0.5verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (9)
  • semaglutide 2.4 mg · weight_eff · Results, paragraph 2 (Figure 2B)
    The change for the trial product estimand was −10·6% (SE 0·4) for semaglutide 2·4 mg versus −3·1% (SE 0·4) for placebo
  • semaglutide 2.4 mg · weight_tp · Table 2
    Bodyweight change from baseline to week 68 (SE), % −9·64% (0·4) −6·99% (0·4) −3·42% (0·4)
  • semaglutide 2.4 mg · ae_dc · Table 3
    Adverse events leading to trial product discontinuation 25 (6·2%) 34 6·4
  • semaglutide 2.4 mg · disc_any · Figure 1 (trial profile)
    47 discontinued treatment prematurely*
  • semaglutide 2.4 mg · nausea · Table 3
    Nausea 136 (33·7%) 249 46·7
  • semaglutide 2.4 mg · vomiting · Table 3
    Vomiting 88 (21·8%) 188 35·3
  • semaglutide 2.4 mg · sae · Table 3
    Serious adverse events 40 (9·9%) 71 13·3
  • semaglutide 2.4 mg · hba1c · Table 2
    Change from baseline to week 68 (SE) −1·6% (0·1) −1·5% (0·1) −0·4% (0·1)
  • semaglutide 2.4 mg · sbp · Table 2
    Change from baseline to week 68 (SE) −3·9 (0·7) −2·9 (0·9) –0·5 (0·8)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.